Adult

Infected Cranioplasty

  • Urgent Micro/ID Consult 
  • Urgent referral to neurosurgery. Source control with surgical management is essential. 
  • Consider drainage of pus, debridement and removal of cranioplasty
  • Modify treatment according to sensitivity test results
  • HIV testing is indicated

Treat empirically if no cultures have been performed before treatment started OR treatment can be guided by previous cultures (i.e. if an infecting organism has been isolated from aspiration of collection). 

Duration of treatment:

  • Superficial infection: 7-10 days 
  • Deep and/or complex infections: may require 4-6 weeks of treatment including oral follow on. For oral option see brain abscess

Preferred empiric treatment

Includes penicillin allergy (non-severe) and patients with MRSA: 

ceftazidime 2g iv tds (If patient is over 80 years of age the usual daily maximum dose of ceftazidime is 3g; this can be increased to 6g daily on advice documented by ID Micro Consultant)

AND

linezolid 600mg po bd (iv if NBM). (See linezolid drug monograph for information about monitoring required)

If unable to have linezolid: substitute linezolid with vancomycin iv

Alternative empiric treatment

For penicillin allergy (severe)

Consult Micro/ID who may recommend: 

linezolid 600mg po bd (iv if NBM). (See linezolid drug monograph for information about monitoring required)

If unable to have linezolid: substitute linezolid with vancomycin iv

PLUS EITHER

Aztreonam 2g iv qds (in patients with a history of penicillin or cephalosporin allergy, aztreonam may be administered without prior testing unless there is a history of ceftazidime allergy)

OR

Ciprofloxacin* 500mg po bd (400mg iv bd if NBM)

Ciprofloxacin may induce seizures in patients with or without a history of seizures – use with caution

*Ensure that the patient is given the Fluoroquinolone MHRA patient information leafletFluoroquinolones, including ciprofloxacin are associated with disabling and potentially long-lasting or irreversible side effects. See Fluoroquinolone antibiotics - severe adverse effects. 

Editorial Information

Last reviewed: 01 Jun 2025